Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
David G. Pfister, Sharon S. Spencer, David J. Adelstein et al. · Journal of the National Comprehensive Cancer Network · 2020
Treatment is complex for patients with head and neck (H&N) cancers with specific site of disease, stage, and pathologic findings guiding treatment decision-making. Treatment planning for H&N cancers involves a multidisciplinary team of experts. This article describes supportive care recommendations in the NCCN Guidelines for Head and Neck Cancers, as well as the rationale supporting a new section on imaging recommendations for patients with H&N cancers. This article also describes updates to treatment recommendations for patients with very advanced H&N cancers and salivary gland tumors, specifically systemic therapy recommendations.
Cited by 1,360 works. doi:10.6004/jnccn.2020.0031
Authors
- David G. Pfister
- Sharon S. Spencer
- David J. Adelstein
- Douglas R. Adkins
- Yoshimi Anzai
- David M. Brizel
- Justine Y. Bruce
- Paul M. Busse
- Jimmy J. Caudell
- Anthony J. Cmelak
- Alexander Dimitrios Colevas
- David W. Eisele
- Moon Jung Fenton
- Robert L. Foote
- Thomas James Galloway
- Maura L. Gillison
- Robert I. Haddad
- Wesley L. Hicks
- Ying J. Hitchcock
- Antonio Jimeno
References
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
- AJCC Cancer Staging Manual
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
- The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus
- Cancer statistics, 2019
- Cancer statistics, 2020
- Cancer statistics, 2015
- The pre-therapeutic classification of co-morbidity in chronic disease
- Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck